摘要
血管生成在肿瘤的进展、侵袭和转移中扮演着重要的角色。血管内皮生长因子是其中一个重要的调节因子,很多肿瘤表现为血管内皮生长因子高表达,并且与肿瘤的预后不良相关。目前针对抗血管生成治疗,一部分在初始治疗即出现耐药,而另外有些则在几个月的治疗后出现耐药。目前耐药的机制尚不完全明了。现综述肿瘤抗血管生成治疗耐药的分子机制的新进展。
Angiogenesis plays an essential role in tumor growth,invasion and metastasis.Vascular endothelial growth factor is one of the key factors responsible for its regulation.High expression of vascular endothelial growth factor has been observed in many cancers,and is associated with worse survival.Many tumors fail to respond initially.Others has resistance after a few months of treatment.The mechanisms of resistance are not well understood.Here is to reviews current knowledge on resistance mechanisms.
出处
《医学综述》
2011年第21期3256-3260,共5页
Medical Recapitulate
关键词
抗血管生成
肿瘤
耐药
Anti-angiogenic
Tumor
Drug resistance